All In Biotech

Investigational drug · Phase 3

Lepodisiran

Also called: LY3819469

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a).

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

4

Any phase or sponsor naming "Lepodisiran"

First trial start

2024

Mar 5, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Lepodisiran", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Atherosclerosis
  • Cardiovascular Diseases
  • Lipoprotein(a)
  • Atherosclerotic Cardiovascular Disease (ASCVD)
  • Elevated Lp(a)

Approved drugs for the same conditions: Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "Lepodisiran" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 64 on PubMed

Also in development for Atherosclerosis

  • ClazakizumabLY5724886, CSL300Phase 32 trials

    Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity

  • YN001Phase 22 trials

    Beijing Inno Medicine Co., Ltd. · Atherosclerosis, Coronary Artery Disease, Atherosclerotic Cardiovascular Disease

  • VERVE-102LY4636581Phase 21 trial

    Eli Lilly · Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.